{"success":true,"data":{"pressRelease":{"id":"58969","rtpr_id":"nPreLFqQGa","ticker":"SCIB","exchange":"Nasdaq Stockholm","all_tickers":["SCIB"],"title":"Study that highlights Nevisense potential for prediction of AD published in leading journal","author":"PR Newswire","published_at":"2026-06-09T13:29:11.517Z","article_body":"Study that highlights Nevisense potential for prediction of AD published in\nleading journal\nPR Newswire\n\nSTOCKHOLM, June 9, 2026\n\nSTOCKHOLM, June 9, 2026 /PRNewswire/ -- SciBase Holding AB (\"SciBase\") (STO:\nSCIB), a leading developer of AI-powered skin health solutions, today\nannounced the publication of a study in the peer-reviewed\njournal Allergy demonstrating that results from Nevisense measurements\nobtained shortly after birth identified children who subsequentially developed\natopic dermatitis (AD).\n\nThe study, which was previously orally presented at the AAAAI conference in\nPhiladelphia February 27 - March 2, was conducted by researchers at the Icahn\nSchool of Medicine at Mount Sinai and assessed neonatal skin barrier integrity\nusing Nevisense within the first days of life. Infants who developed atopic\ndermatitis during their first year had significantly higher neonatal\nmeasurements than those who remained disease-free, suggesting that Nevisense\nmay serve as a non-invasive early biomarker of skin barrier dysfunction\nassociated with future atopic dermatitis risk.\n\nAtopic dermatitis affects approximately 15-20% of children worldwide and is\none of the most common chronic inflammatory skin diseases of infancy and\nchildhood.(1) )It is often the first manifestation of the \"atopic march,\" a\nprogression that may later include food allergies, asthma, and allergic\nrhinitis. The ability to identify skin barrier dysfunction before the onset of\nclinical symptoms could enable earlier risk assessment, support future\nprevention strategies, and improve patient stratification in both clinical\npractice and research.\n\nConclusion from the study was \"Higher EIS scores, suggestive of impaired skin\nbarrier, within the first week of life were significantly associated with\ndevelopment of AD in the first year of life.\"\n\n\"The publication of these findings in a leading peer-reviewed allergy journal\nrepresents an important milestone\", said Pia Renaudin, CEO of SciBase. \"These\nresults support the potential of Nevisense not only as a technology for\nassessing skin barrier integrity, but also as an early biomarker that may help\nidentify infants at increased risk of developing atopic dermatitis before\nclinical symptoms emerge.\"\n\nThe publication adds to a growing body of evidence supporting Nevisense as a\nnon-invasive technology platform for assessing skin barrier integrity and\ndysfunction. Together with previous studies, these findings further strengthen\nthe potential role of Nevisense in earlier risk assessment, prevention\nstrategies, disease monitoring, and future therapeutic development in atopic\ndermatitis and other skin barrier disorders.\n\nThe authors conclude that reliable, non-invasive technologies for assessing\nskin barrier integrity remain an important unmet need. Their findings\ndemonstrate the potential of Nevisense to detect early skin barrier\ndysfunction and identify infants at elevated risk for atopic dermatitis before\ndisease onset.\n\nThe article titled \"Elevated Neonatal Electrical Impedance Spectroscopy\nMeasurements Are Associated With Atopic Dermatitis in High-Risk Infants\" is\npublished in the journal Allergy and can be found through this link:\nhttps://onlinelibrary.wiley.com/doi/10.1111/all.70402.\n\n(1)) Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals\nof Nutrition & Metabolism. 2015;66(Suppl 1):8–16.\n\nFor further information please contact:\n\nPia Renaudin, CEO,\nPhone. +46732069802\nE-mail: pia.renaudin@scibase.com  \n\nCertified Advisor (CA):\n\nDNB Carnegie Investment Bank AB (publ)\nTel: +46 8 588 68 570\nE-mail: certifiedadviser@carnegie.se\n\nAbout SciBase and Nevisense\nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops and commercializes\nNevisense, a unique point-of-care platform that combines AI (artificial\nintelligence) and advanced EIS technology to enhance diagnostic accuracy,\nensuring proactive skin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment\nBank AB (publ). Learn more at www.scibase.com. For press releases and\nfinancial reports visit: http://investors.scibase.se/en/pressreleases\n\nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/scibase/r/study-that-highlights-nevisense-potential-for-prediction-of-ad-published-in-leading-journal,c4359647\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/12371/4359647/4141710.pdf  PR Allergy SciBase  \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/study-that-highlights-nevisense-potential-for-prediction-of-ad-published-in-leading-journal-302795344.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPreLFqQGa","title":"Study that highlights Nevisense potential for prediction of AD published in leading journal","author":"PR Newswire","ticker":"SCIB","created":"2026-06-09T13:29:11.517Z","tickers":["SCIB"],"exchange":"Nasdaq Stockholm","article_body":"Study that highlights Nevisense potential for prediction of AD published in\nleading journal\nPR Newswire\n\nSTOCKHOLM, June 9, 2026\n\nSTOCKHOLM, June 9, 2026 /PRNewswire/ -- SciBase Holding AB (\"SciBase\") (STO:\nSCIB), a leading developer of AI-powered skin health solutions, today\nannounced the publication of a study in the peer-reviewed\njournal Allergy demonstrating that results from Nevisense measurements\nobtained shortly after birth identified children who subsequentially developed\natopic dermatitis (AD).\n\nThe study, which was previously orally presented at the AAAAI conference in\nPhiladelphia February 27 - March 2, was conducted by researchers at the Icahn\nSchool of Medicine at Mount Sinai and assessed neonatal skin barrier integrity\nusing Nevisense within the first days of life. Infants who developed atopic\ndermatitis during their first year had significantly higher neonatal\nmeasurements than those who remained disease-free, suggesting that Nevisense\nmay serve as a non-invasive early biomarker of skin barrier dysfunction\nassociated with future atopic dermatitis risk.\n\nAtopic dermatitis affects approximately 15-20% of children worldwide and is\none of the most common chronic inflammatory skin diseases of infancy and\nchildhood.(1) )It is often the first manifestation of the \"atopic march,\" a\nprogression that may later include food allergies, asthma, and allergic\nrhinitis. The ability to identify skin barrier dysfunction before the onset of\nclinical symptoms could enable earlier risk assessment, support future\nprevention strategies, and improve patient stratification in both clinical\npractice and research.\n\nConclusion from the study was \"Higher EIS scores, suggestive of impaired skin\nbarrier, within the first week of life were significantly associated with\ndevelopment of AD in the first year of life.\"\n\n\"The publication of these findings in a leading peer-reviewed allergy journal\nrepresents an important milestone\", said Pia Renaudin, CEO of SciBase. \"These\nresults support the potential of Nevisense not only as a technology for\nassessing skin barrier integrity, but also as an early biomarker that may help\nidentify infants at increased risk of developing atopic dermatitis before\nclinical symptoms emerge.\"\n\nThe publication adds to a growing body of evidence supporting Nevisense as a\nnon-invasive technology platform for assessing skin barrier integrity and\ndysfunction. Together with previous studies, these findings further strengthen\nthe potential role of Nevisense in earlier risk assessment, prevention\nstrategies, disease monitoring, and future therapeutic development in atopic\ndermatitis and other skin barrier disorders.\n\nThe authors conclude that reliable, non-invasive technologies for assessing\nskin barrier integrity remain an important unmet need. Their findings\ndemonstrate the potential of Nevisense to detect early skin barrier\ndysfunction and identify infants at elevated risk for atopic dermatitis before\ndisease onset.\n\nThe article titled \"Elevated Neonatal Electrical Impedance Spectroscopy\nMeasurements Are Associated With Atopic Dermatitis in High-Risk Infants\" is\npublished in the journal Allergy and can be found through this link:\nhttps://onlinelibrary.wiley.com/doi/10.1111/all.70402.\n\n(1)) Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals\nof Nutrition & Metabolism. 2015;66(Suppl 1):8–16.\n\nFor further information please contact:\n\nPia Renaudin, CEO,\nPhone. +46732069802\nE-mail: pia.renaudin@scibase.com  \n\nCertified Advisor (CA):\n\nDNB Carnegie Investment Bank AB (publ)\nTel: +46 8 588 68 570\nE-mail: certifiedadviser@carnegie.se\n\nAbout SciBase and Nevisense\nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops and commercializes\nNevisense, a unique point-of-care platform that combines AI (artificial\nintelligence) and advanced EIS technology to enhance diagnostic accuracy,\nensuring proactive skin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment\nBank AB (publ). Learn more at www.scibase.com. For press releases and\nfinancial reports visit: http://investors.scibase.se/en/pressreleases\n\nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/scibase/r/study-that-highlights-nevisense-potential-for-prediction-of-ad-published-in-leading-journal,c4359647\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/12371/4359647/4141710.pdf  PR Allergy SciBase  \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/study-that-highlights-nevisense-potential-for-prediction-of-ad-published-in-leading-journal-302795344.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-09T13:29:11.577098987Z","server_sent_at_ms":1781011751577},"received_at":"2026-06-09T13:29:11.636Z","source_url":null},"analysis":{"id":"48398","press_release_id":"58969","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"SciBase announced the publication of a study in the peer-reviewed journal Allergy, demonstrating that Nevisense measurements taken shortly after birth can identify infants who later develop atopic dermatitis.\n\nThe study, conducted by researchers at the Icahn School of Medicine at Mount Sinai, found that higher neonatal electrical impedance spectroscopy scores were significantly associated with the development of atopic dermatitis within the first year of life.\n\nCEO Pia Renaudin stated that the results support Nevisense's potential as an early biomarker for skin barrier dysfunction, enabling risk assessment before clinical symptoms emerge.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Peer-reviewed validation of Nevisense as an early biomarker for atopic dermatitis strengthens SciBase's scientific moat."},"keyFigures":{"customDimensions":{"ad_prevalence_children":"15-20%"}},"quotedText":"These results support the potential of Nevisense not only as a technology for assessing skin barrier integrity, but also as an early biomarker that may help identify infants at increased risk of developing atopic dermatitis before clinical symptoms emerge.","namedEntities":{"people":[{"name":"Pia Renaudin","role":"CEO"}],"products":["Nevisense","EIS"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"Icahn School of Medicine at Mount Sinai","relationship":"research partner"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified advisor"},{"name":"Karolinska Institute","relationship":"research origin"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Publication of a peer-reviewed study in a leading journal (Allergy) validates the core technology (Nevisense) as a potential early biomarker for atopic dermatitis. This is a significant scientific milestone for a pre-commercial/early-stage medtech company, strengthening its IP and commercial narrative, though it is not a regulatory approval or revenue-generating event."},"tickerRelevance":{"others":[],"primary":"SCIB"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"scientific_publication","sectorWeight":"biotech_medtech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"SciBase announced the publication of a study in the peer-reviewed journal Allergy, demonstrating that Nevisense measurements taken shortly after birth can identify infants who later develop atopic dermatitis.\n\nThe study, conducted by researchers at the Icahn School of Medicine at Mount Sinai, found that higher neonatal electrical impedance spectroscopy scores were significantly associated with the development of atopic dermatitis within the first year of life.\n\nCEO Pia Renaudin stated that the results support Nevisense's potential as an early biomarker for skin barrier dysfunction, enabling risk assessment before clinical symptoms emerge.","key_figures":{"customDimensions":{"ad_prevalence_children":"15-20%"}},"named_entities":{"people":[{"name":"Pia Renaudin","role":"CEO"}],"products":["Nevisense","EIS"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"Icahn School of Medicine at Mount Sinai","relationship":"research partner"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified advisor"},{"name":"Karolinska Institute","relationship":"research origin"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-09T13:30:20.078Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"scientific_publication","sectorWeight":"biotech_medtech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":68429,"modelName":"george-droid-qwen-72b"}}